METHOD FOR DETERMINING THE PROBABILITY OF HEPATIC FIBROSIS IN PATIENTS PREVIOUSLY SUFFERING FROM COVID-19 Russian patent published in 2022 - IPC A61B6/03 A61B5/93 A61B5/107 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular, to gastroenterology. The severity of suffered infection is found out from the patient, the body mass index and the data on the levels of gases in the exhaled air are measured. The data on the severity of the suffered Covid-19 infection, the values of body mass index and the data on the levels of gases in the exhaled air are then compared. If a patient has suffered Covid-19 in the form of ARVI, patient’s body mass index is less than or equal to 30 kg/m², the patient is non-producer of hydrogen or methane, slow colonic transit has not been identified, there are no signs of excessive bacterial growth syndrome, then the patient has a low probability of the presence of hepatic fibrosis. If the patient has suffered Covid-19 in the form of pneumonia with 5 to 30% of the lung tissue affected, the body mass index is in the range from 31 to 35 kg/m², the patient is a non-producer of hydrogen or methane, slow colonic transit is identified, no signs of bacterial overgrowth syndrome are present, then the patient has an average probability of the presence of hepatic fibrosis. If the patient has suffered Covid-19 in the form of pneumonia with more than 30% of the lung tissue affected, the body mass index exceeds 35 kg/m², the patient is not a non-producer of hydrogen or methane, slow colonic transit is not identified, signs of bacterial overgrowth syndrome are present in the small intestine, then the patient has a high probability of the presence of hepatic fibrosis.

EFFECT: method allows for identification of the presence of hepatic fibrosis regardless of the etiology of the disease, identification of the group of patients in need of in-depth examination for diffuse hepatic pathology, a change in the tactics of therapy in a short time, wherein the method is non-invasive, preventing possible complications in the health of the patient; method also has a high sensitivity, specificity, and high diagnostic accuracy, and also has clear criteria for estimating the probability of the presence of hepatic fibrosis in patients previously suffering Covid-19.

1 cl, 1 dwg, 4 tbl, 3 ex